Last reviewed · How we verify
L-ARG+GHRH
L-ARG+GHRH is a Growth hormone secretagogue / amino acid combination Small molecule drug developed by AEterna Zentaris. It is currently in Phase 3 development for Adult growth hormone deficiency, Age-related growth hormone decline / somatopause. Also known as: Test Control.
L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair.
L-arginine combined with growth hormone-releasing hormone (GHRH) stimulates endogenous growth hormone secretion to promote anabolic effects and tissue repair. Used for Adult growth hormone deficiency, Age-related growth hormone decline / somatopause.
At a glance
| Generic name | L-ARG+GHRH |
|---|---|
| Also known as | Test Control |
| Sponsor | AEterna Zentaris |
| Drug class | Growth hormone secretagogue / amino acid combination |
| Target | GHRH receptor (GHRHR); nitric oxide pathway |
| Modality | Small molecule |
| Therapeutic area | Endocrinology / Metabolic disorders |
| Phase | Phase 3 |
Mechanism of action
L-arginine is an amino acid that serves as a substrate for nitric oxide synthesis and may enhance GHRH signaling, while GHRH is a peptide hormone that directly stimulates the anterior pituitary to release growth hormone. Together, this combination aims to synergistically increase circulating GH levels, promoting muscle protein synthesis, bone formation, and metabolic improvements in conditions characterized by growth hormone deficiency or age-related decline.
Approved indications
- Adult growth hormone deficiency
- Age-related growth hormone decline / somatopause
Common side effects
- Injection site reactions
- Headache
- Flushing
- Hyperglycemia
Key clinical trials
- Investigation of a New, Oral Growth Hormone Secretagogue, AEZS-130 as a Growth Hormone Stimulation Test. (PHASE3)
- Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers (PHASE1)
- Diagnosing Adult Growth Hormone Deficiency (NA)
- Role of Endogenous Estrogen in Growth-Hormone Regulation in Postmenopausal Women (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- L-ARG+GHRH CI brief — competitive landscape report
- L-ARG+GHRH updates RSS · CI watch RSS
- AEterna Zentaris portfolio CI
Frequently asked questions about L-ARG+GHRH
What is L-ARG+GHRH?
How does L-ARG+GHRH work?
What is L-ARG+GHRH used for?
Who makes L-ARG+GHRH?
Is L-ARG+GHRH also known as anything else?
What drug class is L-ARG+GHRH in?
What development phase is L-ARG+GHRH in?
What are the side effects of L-ARG+GHRH?
What does L-ARG+GHRH target?
Related
- Drug class: All Growth hormone secretagogue / amino acid combination drugs
- Target: All drugs targeting GHRH receptor (GHRHR); nitric oxide pathway
- Manufacturer: AEterna Zentaris — full pipeline
- Therapeutic area: All drugs in Endocrinology / Metabolic disorders
- Indication: Drugs for Adult growth hormone deficiency
- Indication: Drugs for Age-related growth hormone decline / somatopause
- Also known as: Test Control
- Compare: L-ARG+GHRH vs similar drugs
- Pricing: L-ARG+GHRH cost, discount & access